Senseonics Holdings, Inc.
SENSHealthcareNASDAQMedical Devices · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSenseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the. The company carries a $358.6M market cap, placing it firmly in the small-cap category. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Market Cap
$358.6M
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-3.13
EPS (TTM)
$-1.97
EPS (Fwd)
$-2.19
ROE
-168.3%
ROA
-37.7%
Cash
$94.0M
Total Debt
$41.4M
Free CF
-$46.5M
52W Change
-35.8%
Annual Financials
Cash vs Debt
Senseonics Holdings, Inc. holds $94.0M in cash against $41.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$46.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -168.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $16.4M (2022) to $35.3M (2025), reflecting a 115% increase over the period.
With cash comfortably exceeding debt, SENS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SENS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.